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ABSTRACT 
 
In Vitro Evolutionary Dynamics of C. albicans during Adaptation to Fluocnazole. 
(August 2012) 
Mian Huang, B.S., Tianjin University 
Chair of Advisory Committee: Dr. Katy C. Kao 
 
Many drug-resistant mechanisms in Candida albicans (C. albicans), a clinical important 
fungal pathogen, have been well characterized.  However, few studies investigated the 
emergence of drug resistance from the evolutionary perspective and little is known about 
the evolutionary trajectories during the adaptation to the drug.  Here, we examined the 
evolutionary dynamics of C. albicans both in the presence and absence of fluconazole, a 
first line drug, using the visualizing evolution in real-time (VERT) method. 
 
Evolutionary dynamics of replicate C. albicans populations, either in the presence or 
absence of fluconazole, were determined and adaptive mutants arose in the populations 
were systematically isolated using the VERT method.  Drug susceptibility assays were 
performed to measure the fluconazole minimum inhibitory concentration (MIC) for the 
adaptive isolates from drug-exposed populations.  Analysis of the evolutionary dynamics 
revealed that mutations arose more frequently in the presence of the drug compared to 
the absence of the drug and the drug-resistant mutations occurred in independent 
lineages, suggesting a heterogeneous nature of the populations during the adaptation.  In 
  
iv 
 
addition, fitness effects were evaluated for each adaptive mutant both in the presence 
and absence of drug and we found most of them gained significant increase in the drug 
resistance without a fitness cost in the absence of the drug.  Interestingly, the aneuploidy 
and gross chromosomal rearrangements, common drug-resistant mechanisms, were not 
responsible for the increased resistance to fluconazole of most adaptive isolates, 
suggesting single-nucleotide polymorphisms (SNPs) or other stable unknown 
chromosomal rearrangements may contribute to the increased drug resistance. 
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1. INTRODUCTION 
 
Invasive infections caused by fungal pathogens are increasingly recognized as major 
challenges in public health.  C. albicans is among the most frequent fungal species 
isolated from the clinical specimens and represents the most common cause of 
Candidiasis.  The emergence of antifungal drug resistance in this organism is rapid both 
during the infection of a host system and laboratory adaptive evolution, further 
deepening the public health concern over this fungal pathogen.  The drug resistance 
development in pathogens is a process of adaptive evolution during which genetic 
mutations will emerge and undergo the selection of the environmental stresses.  The 
populations undergoing the adaptive evolution may be heterogeneous in their genotypes, 
depending on the population size, the rate of mutation, and the fitness effect associated 
with mutations.  Thus, clonal interference may occur during the adaptive evolution, 
leading to the loss of many beneficial mutations due to the competition among multiple 
adaptive genotypes for expansion in populations (28, 42).  Determining the evolutionary 
dynamics during the adaption is important for understanding the fundamental principles 
underlying how eukaryotic pathogens evolve resistance to antimicrobial agents, since it 
provides a direct observation of the population’s adaptive evolution and records the 
____________ 
This thesis follows the style of Eukaryotic Cell. 
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continuous dynamic process in terms of the arising and expansion of the adaptive 
mutants. 
 
The significance of the evolutionary dynamics not only lies in the useful information on 
adaptation provided by it, such as the frequencies with which adaptive mutants emerge 
and expand, but also in that it enables the systematic analysis of the adaptive events 
occurred in sequence during the adaption.  These are important for both theoretical 
studies and practical applications.  For example, whether the evolution of an organism 
follows similar adaptive mechanisms is a critical and intriguing question in theoretical 
study.  Evolutionary dynamics enables us to analyze and determine the evolutionary 
trajectories (the order of occurrence of adaptive mutations) of populations during the 
adaptation.  By comparing evolutionary trajectories determined from parallel 
populations we are able to gain some insights into the question.  In practical applications, 
knowledge of the frequency and evolutionary trajectories of the drug-resistant 
populations and whether specific patterns of the trajectories are correlated with the level 
of drug resistance ultimately achieved in the populations can be used to predict the likely 
trajectory of a clinical infection and to develop appropriate therapeutic strategies. 
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In addition, although drug resistance mechanisms in C. albicans have been extensively 
studied, more new molecular bases and cellular pathway involved in the development of 
drug resistance remain to be characterized (136).  The analysis of the evolutionary 
dynamics is able to facilitate the systematic isolations of the adaptive clones and thus 
help to discover novel drug-resistant mechanisms and relevant pathways.  
 
The aim of this thesis was to understand how C. albicans evolves resistance to 
fluconazole, an antifungal agent, during the in vitro adaptive evolution, using the 
visualizing evolution in real-time (VERT) system.  This included: 
1. establishing a systemic approach to monitor the in vitro adaptive evolution of C. 
ablicans in terms of the alteration in population structure, 
2. determination of the in vitro evolutionary dynamics of C. albicans both in the 
absence and presence of the fluconazole, 
3. identification and isolation of adaptive mutants from the evolved experimental C. 
albicans populations, 
4. characterization of the drug-resistant mechanisms and evaluation of  their fitness 
effects. 
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The VERT system for C. albicans was established to analyze the adaptation of the 
fungal pathogen in continuous culture under increasing concentrations of fluconazole.  
The evolution of the organism under same conditions except the presence of the 
antifungal agent served as the control.  A set of isogenic strains differing only in the 
fluorescent markers were generated to divide the whole population into different 
subpopulations, which helps to visualize the occurrence of adaptive events, to measure 
the frequency, and to facilitate the isolation of the adaptive mutants.  FACS was used to 
determine the proportion of different subpopulations in real time during the adaptive 
evolution and the collected fluorescence distribution data of the C. albicans populations 
was used to plot the evolutionary dynamics.  According to the evolutionary dynamics a 
series of adaptive events were identified in sequence and single colonies probably 
responsible for the events were thus isolated.  Drug resistance levels of these adaptive 
clones were then determined by fluconazole MIC measurements and the stability tests 
were performed on these clones with increased drug resistance to exclude the possibility 
of transient physiological response.  For those adaptive clones with stable drug resistant 
phenotype, contour-clamped homogeneous electric field (CHEF) karyotype analysis and 
flow cytometry were used to examine the gross chromosome rearrangements and strain 
ploidy respectively.  Strains displaying karyotypes that are different from the wild-type 
C. albicans underwent further microarray analysis to identify the DNA present in the 
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extra bands.  Pairwise competition assays under similar conditions to the evolutionary 
environment were performed both in the presence and absence of the fluconazole to 
evaluate the relative fitness coefficients of all adaptive clones against either the parental 
strain or the previous adaptive strain. 
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2. BACKGROUND AND LITERATURE REVIEW 
 
2.1 The Genus Candida 
The genus Candida is a member of the phylum Ascomycota, the largest phylum of fungi 
with over 64000 species, which includes many species of industrial significance such as 
S. cerevisiae and many important human pathogens such as Aspergillus spp. and 
Cryptococcus spp.  Species from the genus Candida usually colonize in human body as 
commensals and belong to the normal microbial flora of skin and mucosal surface, 
including oral cavity, gastrointestinal tract, and genitourinary tract.  
 
Candida spp. is a group of important opportunistic pathogens.  When the balance of the 
normal microbial flora is disrupted or the host immune system is compromised, these 
fungal pathogens may cause superficial infections of mucosal epithelial tissue and even 
life-threatening invasive infections.  The superficial candidosis includes chronic atrophic 
stomatitis, chronic mucocutaneous candidosis and vulvovaginitis, while the severe 
invasive infections include bloodstream infections and infections of deep organs.  
Candida spp. are the fourth most common pathogenic agents responsible for nosocomial 
bloodstream infection in the United States (143) and the third and fourth most common 
cause of urinary tract infection (10) and catheter-related bloodstream infection (84), 
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respectively, in Europe.  In addition, they are also responsible for 13.2% of all intra-
abdominal infections (104) and 4% of bloodstream infection after stem cell 
transplantation with a high crude mortality (42%) (88).  
 
Although the distribution of Candida species in clinic isolates varies significantly across 
different host niches, C. albicans remains to be the most frequently isolated species 
among all Candida species (~50% in North America) (91).  However, the role of the 
non-albicans Candida (NAC) in the Candidiasis is becoming more and more important, 
as reflected by the increase in the proportion of NAC in clinical isolates.  In 1970-1990, 
NAC represented 10-40% of all candidemias, and increased to 35-65% in 1991-1998 
(60).  NAC species are more frequently isolated from cancer patients, especially those 
with haematological malignancies and bone marrow recipients (40-70%), and less likely 
from intensive care unit (ICU) and surgical patients (35-55%), children (1-35%), and 
HIV-infected patients (0-33%) (60).  Among NAC, the most common species include C. 
tropicalis, C. glabrata, C. krusei and C. parapsilosis, which together account for about 
one half of all bloodstream infections (60).  C. parapsilosis, the second most common 
isolates, is mainly responsible for bloodstream infections associated with catheters, 
hyperalimentation, premature infants, or contaminated prosthetic devices (60).  C. 
tropicalis is frequently isolated from cancer, neutropaenic and bone marrow transplant 
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(BMT) patients (130, 140).  C. glabrata is also considered to be the second most 
common isolates responsible for systemic infections caused by Candida spp. according 
to some studies (56, 143) and has a high inherent resistance to some commonly used 
antifungal agents such as fluconazole.  C. krusei has a predilection for neutropenic adult 
cancer patients (139) and has a high natural resistance to azoles as well.  Less common 
Candida spp, such as C. lusitaniae, C. guilliermondii and other rare species such as C. 
rugosa, C. pseudotropicalis, C. stellatoidea, C. norvegensis and C. famata, have also 
been reported in clinics.  
 
Compared to the C. albicans, some NAC species may cause more severe infections due 
to following two factors.  First, a higher mortality rate associated with infections, 
especially severe systemic infections, caused by some NAC species have been reported 
in many studies (29, 139).  Second, the high inherent resistance to antifungal agents was 
observed in some NAC species such as C. krusei and C. glabrata, limiting the antifungal 
therapy options and contributing to the increase in the failure of therapeutic treatments.  
Therefore, species identification is essential for the design of antifungal therapy against 
infections caused by Candida spp. and species-specific strategies should be adopted 
based on the causative infectious agent identified.  
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2.2 Candida albicans 
2.2.1 General Characteristics of C. albicans 
C. albicans has a heterozygous diploid genome of about 32 Mb, which is slightly larger 
than that of Saccharomyces cerevisiae (S. cerevisiae), and is believed to be an obligate 
diploid.  It contains eight pairs of chromosomes which can be separated by pulse-field 
gel electrophoresis (75). Variability in karyotypes of the genome is frequently observed 
in C. albicans clinical isolates, mostly as a result of changes in the number of the 
ribosomal DNA (rDNA) repeats (98, 138) and reciprocal translocation events between 
multiple repeat sequences (MRS) (21, 22, 124).  In addition, high frequency of genome 
rearrangements occur in this opportunistic pathogen through non-disjunction or other 
cryptic mechanisms, leading to the loss of single or multiple chromosomes or formation 
of isochromsomes.  This has been shown to be an important mechanism for C. albicans 
to adapt to a variety of environmental stresses.  For example, the loss of chromosome 5 
was frequently found in strains growing on sorbose as the sole carbon source (51) and 
the loss of chromosome 4 and the gain of chromosome 3 have a higher incidence in 
strains resistant to fluconazole (90).  
 
The genomes for two C. ablicans strains, SC5314 and WO1, have been fully sequenced.  
The sequencing of the former was completed by the Stanford Genome Technology 
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Center (12, 52) and the latter by the Broad Institute of MIT and Harvard.  Comparative 
genome studies of the sequenced strains revealed that many open reading frames (ORFs) 
in C. albicans have homologues in S. cerevisiae, such as those related to the mating 
machinery (128), while others encode novel gene products, such as proteases, lipases, 
cell-wall proteins and genes important for host interactions.  Although many C. albicans 
genes have homologues in S. cerevisiae, prediction of their functions based on the 
sequence similarity is not always accurate and sometimes may lead to wrong 
conclusions.  A good example of genes with high sequence identity but different 
functions between these two fungi is SPT3. Mutation in S. cerevisiae SPT3 causes a 
defect in filamentous growth while spt3 mutants in C. albicans are hyperfilamentous 
(63).  
 
Few detailed studies on the biochemical characteristics of this important opportunistic 
pathogen currently exist.  Contradictory results were often obtained in these studies, 
which is not surprising due to the diverse origins of the subjects, different experimental 
conditions and the ability of the pathogen to switch from yeast to filamentous form.  
Some general metabolic characteristics of this organism were summarized here.  C. 
albicans can grow on a simple defined medium with a carbon source, nitrogen source, 
phosphate and supplement of biotin (115).  The temperature and PH range suitable for its 
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growth is between 20-40℃ and 2-8 respectively.  Growth rates of C. albicans on defined 
medium at 30℃ generally ranges from 0.3 to 0.4 hr-1 in continuous culture (115) and it 
seems no significant difference in the growth rate exists between its two distinct 
morphological forms.  
 
C. albicans possesses all three major intact carbon metabolic pathways, including the 
Embden-Meyerhof pathway (EMP), pentose phosphate pathway (PPP), and tricarboxylic 
acid cycle (TAC).  It can utilize a variety of carbon source, such as glucose, galactose, 
and maltose, and produce acid and gas.  The utilization of glucose in this fungus is 
mainly through the EMP, since 60-80% of the glucose flux is through this pathway (9).  
C. albicans uses both glycogen and trehalose as energy store, while the glycogen was 
chosen to be the principle store of intracellular carbon source (123). 
 
Studies on the respiratory system of C. albicans showed it is different from the classical 
pathway that is mediated by cytochrome c oxidase and instead it possesses an alternate 
oxidase similar to the alternate cyanide-insensitive pathway identified in many other 
plants and yeasts (46, 47, 58, 59).  This alternate oxidase seems express at all stages of 
growth and in both filamentous forms and yeast forms (114).  Cynaide and antimycin A, 
inhibitors of the normal cytochrome pathway, didn’t affect the activity of the alternate 
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oxidase and so did chloramphenicol and cycloheximide (114).  However, the cryptic 
alternate oxidase is sensitive to the presence of Salicyl-hydroxamic acid (114).  All of 
these evidences confirmed the existence of alternate respiratory pathway in C. albicans. 
 
2.2.2 Virulence Factors of C. albicans  
Many factors have been found to be associated with the virulence in the C. albicans 
through extensive in vivo studies of the animal models.  They include host recognition 
biomolecules, morphogenesis, and enzymes related to the host invasion.  These factors 
play key roles in the pathogenicity of this organism, but it is also important to notice that 
these factors may not only be restricted to the pathogenic states.  Thus, prediction of a 
pathogenic strain cannot only be made based on the existence of these virulence factors. 
 
Adhesins, a large group of biomolecules promoting the adherence of pathogens to their 
host or host-cell ligands, are involved in the host recognition process.  Five genes which 
have been assigned an adhesin function in C. albicans are discussed here, including 
ALS1, ALA1, HWP1, INT1, and MNT1.  These genes have already been isolated and their 
functions were briefly described in table 1.  ALS1 of C. albicans has a S. cerevisiae 
homologue which encodes the ɑ-agglutinin protein responsible for cell-cell interaction 
during the mating process and is a member of the agglutinin-like sequence (ALS) family.  
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ALA1 encodes another protein belonging to the same family as ALS1 and both of them 
seem to have an adhesin function (37, 40, 41).  HWP1 encodes a mannoprotein with its 
N-terminal domain thought to be exposed to the surface and the C-terminus covalently 
integrated with cell wall β-glucan (120).  Disruption of the gene led to a reduced 
virulence in a hematogenously disseminated murine model (119).  Consistently, another 
mutant of the gene caused a decline in the mortality and the rate of reproduction in the 
kidneys of infected mice and did less damage to the endothelial cells as well (127).  
INT1 has been identified as a putative integrin gene in C. albicans(38).  Genes from the 
integrin family of mammalian cells are required for binding to the extracellular matrix 
ligands.  Although INT1 of C. albicans has a low identity compared with the sequences 
of mammalian integrin genes, several evidence confirmed its role in adherence of C. 
albicans and formation of its filamentous form (39), including the binding of the C. 
albicans yeast cells to antibody that is against the divalent cation-binding domain and 
formation of elongated cells due to the heterologous expression of the gene in S. 
cerevisiae.  In addition, the deletion of the INT1 reduced the virulence and adherence to 
epithelial cells and caused a deficiency in filamentous growth on milk-tween and Spider 
agar.  MNT1 encodes a type II membrane protein which is required for both O- and N-
mannosylation in fungi.  Deletion of the gene will decrease the ability of in vitro 
adherence and cause the mutants loss of the virulence (14). 
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Table 1. Adhesins of Candia albicans and Candida glabrata  
 
(taken from(Richard and William, 2001)) (15) 
 
 
 
Morphogenesis is another important virulence factor, representing the ability of cells to 
switch from a yeast form to a filamentous form.  The filamentous form is thought to be 
related to the virulence and pathogenicity of C. albicans.  However, no determinative 
evidence was obtained yet.  A more rational perspective on the relationship between the 
morphology and the host invasion may stress the importance of the flexibility of the 
morphological change instead of the advantages of a specific morphological form in the 
disease development.  Morphogenesis pathways of C. albicans were extensively studied 
and two of them have been characterized in details (13, 65, 68).  Components of one 
pathway are homologous to those of STE12 mating and pseudohyphae pathway of S. 
cerevisiae, including CPH1, CST20, HST7, STE7, and CEK1.  CPH1 is the C. albicans 
homologue of STE12 and others mentioned above are homologous to components of 
mitogen-activated protein kinase (MAPK) pathway, which regulates the phosphorylation 
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of Cph1p.  In addition, Cpp1p, a protein phosphatase, is another regulatory component 
which regulates Cek1p in the pathway (27).  Another pathway consists of Egf1p, a 
transcription factors, and components such as homologues of Ras proteins, adenyl 
cyclase and protein kinase A (TPK2) (13, 65, 68, 122).  This pathway is independent to 
the first one and mutants with one important component,RAS1,disrupted failed to start 
filamentous growth in response to serum but did form pseudohyphae (34).  
  
Some degradative enzymes are potential virulence factors as well, including members of 
secreted aspartyl proteinases (SAP) family and phospholipases (PL) family.  Plb1p, a 
typical member of PL family, encodes a glycoprotein with both hydrolase and 
lysophospholipase-transacylase activity.  Deletion of the gene caused a reduced 
virulence in a murine model of candidasis.  In addition, a drop in the in vitro production 
and the activity of phospholipase has been detected at the tips of hypha during the host 
invasion when the gene is disrupted (43).  In C. albicans SAP family consists of at least 
nine members (80).  Depending on different model system, different members may be 
required for the host invasion of the pathogen.  SAP1-6 were correlated to the virulence 
in guinea pig and murine models (100), while SAP1-3 were required for the invasion in 
cultured human oral tissue and lesions (105). 
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Phenotypic switching was a frequently observed phenomenon in C. albcians strains.  It 
is usually accompanied by changes in colony morphology (such as shape, color, and 
surface structure) as well as differential expression of phenotype-specific genes (81, 116, 
117).  The plasticity of the organisms contributed by the phenotypic switching may be 
responsible for its ability to colonize in multiple anatomically distinct host niches as well 
as to adapt to a variety of environmental stresses imposed by the hosts, microbial 
competitors, and antifungal treatments.  Thus, the phenotypic switching is a promising 
candidate of the virulence factors.    
 
2.2.3 Antifungal Drugs and Drug Resistance Mechanisms in C. albicans 
Currently, there are four major classes of antifungal agents used to treat infections 
caused by C. albicans, including the fluorinated pyrimidine analogue, polyenes, azoles 
and echinocandins.  Each class has its own target and acts in different working 
mechanism, which are summarized in figure 1.  Among the existing antifungal drugs, 
azoles are most commonly used, due to their low toxicity and their oral availability.  
However, the fact that they are fungistatic rather than fungicidal provides a clear 
opportunity for the evolution of drug resistance during long periods of prophylactic 
treatment (93). 
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The mechanisms of resistance to azole drugs in C. albicans have been studied 
extensively.  The majority of them confer drug resistance on the fungal cells either by 
reducing the intracellular drug concentration or inhibiting the interaction between the 
antifungal agent and its target.  These mechanisms can be acquired both in vivo and in 
vitro by many ways, including the small-scale point mutations, the loss of heterozygosity 
(LOH), and the aneuploidy which usually involves large-scale genomic rearrangements 
(109, 111, 112). 
 
 
 
 
FIG. 1. Targets of Antifungal Agents (a) and Drug-Resistant Mechanims (b) in Candida albicans. 
Grey lettering indicates mutated proteins and bold lettering indicates protein overexpression. 5-FU, 5-
fluorouracil; 5-FUMP, 5-fluorouridine monophosphate (taken from (Richard et al., 2007)) (16). 
 
 
 
C. ablicans may reduce the amount of the drug that penetrates its cytoplasm membrane 
and reaches to the target either by changing the membrane components (71) or 
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expressing more multidrug transporters (73, 129).  The change in the membrane 
components may alter the membrane barrier functions and thus block the influx of the 
antifungal agents into the cytoplasm, resulting in the reduction of the intracellular 
concentration of the drugs.  On the other hand, more multidrug transporters were 
expressed in some mutants, leading to a more active efflux of intracellular drugs, and 
thus achieve the similar result.  Multidrug transporters associated with drug resistance in 
C. albicans are the products encoded by CDR1, CDR2, and MDR1.  The two CDR genes 
encode two ATP-binding cassette (ABC) transporters while the MDR1 gene encodes a 
major facilitator and their upregulation were observed in many clinical azole-resistant 
isolates (101, 102, 141, 142). 
 
C. albicans may alter the drug targets to minimize the drug effect on the cells by 
changing its amounts and structures.  Either expressing more drug target or reducing the 
target’s affinity to the drug can confer drug resistance on the cells.  The major target for 
azoles in C. albicans is a cytochrome P450, encoded by ERG11, which catalyzes the 
demethylation of the sterol in its 14α position.  Drug-resistant mutants can increase the 
amount of the Erg11p expressed by either the duplication of the gene or upregulation of 
the gene’s transcription (78, 136).  Many point mutations in ERG11 gene were detected 
in the drug-resistance clinical isolates of C.albicans (72, 135) and some, such as G464S 
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(55) and R467K (61) ,were shown to reduce the affinity of the gene product to antifungal 
agents by altering the heam-binding domain of the drug target. 
 
High level of heterozygosity was found in C. albicans (94, 125, 132, 133) as well.  The 
LOH in this fungus, either by mitotic recombination or chromosome rearrangement, is 
shown to be correlated with the drug resistance (23, 36, 135).  It not only occurs in the 
open reading frames (ORF), but also in promoter regions.  Therefore, the LOH may 
affect functions of proteins by altering their structures and can also change the 
expression patterns of genes in the transcriptional level.  A good example showing the 
transcriptional effect of the LOH is the allelic variation in the promoter region of SAP2, 
a pathogenicity-related gene of C. albicans, which leads to the differential regulation of 
the two SAP2 alleles (121).  The LOHs at other two genetic loci, ERG11 and TAC1, are 
of particular interest since they were correlated with the acquisition of drug resistance.  
In addition to LOH, aneuploidy is also shown to be associated with the emergence of 
drug resistance in clinical isolates and laboratory evolved strains (109, 111, 112).  A 
study monitored the dynamics of gross chromosomal rearrangements in C. albicans 
populations during the in vitro evolution both in the presence and absence of fluconazole 
(112).  In this study, multiple aneuploidies were detected in populations evolved with the 
drug while not found in the non drug-exposed populations and among the multiple 
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aneuploidies detected, formation of isochromosome 5L (i(5L)) was correlated to the 
acquisition of drug resistance.  Interestingly, they further observed that the early 
appearance of i(5L) was only detected in populations which acquired high level of drug 
resistance in the end of their evolutions. 
 
Furthermore, alterations in the fungal metabolism and formation of the dense biofilm 
may contribute to the increased antifungal resistance as well.  Clinical drug-resistant 
strains with mutations in the ERG3 gene were isolated and their drug resistance was 
correlated to the erg3 mutations.  Mutations in ERG3 will produce inactive sterol ∆5, 6 
desaturases and thus prevent the formation of toxic metabolite when normal sterol 
synthesis pathway was blocked (54, 87), reducing the cytotoxcity of some antifungal 
agents.  Studies also showed that C. albicans cells in the biofilm are more resistant to 
drugs such as azoles and amphotericin B compared to their planktonic form (17). 
 
2.2.4 Mating in C. albcians 
C. albicans was long thought to be an asexual fungus which exists only as an obligate 
diploid.  However, evidence suggesting the existence of mating in this fungus was 
reported in many studies.  An important discovery related to the mating in C. albicans 
was made in 1999 by Hull CM and Johnson AD (49).  They identified a mating-type like 
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(MTL) locus in C. albicans and genes residing at the locus include homologues of many 
key regulators of mating in S. cerevisiae, such as MTLa1, MTLɑ1, and MTLɑ2.  In 
addition, a novel transcriptional regulator MTLa2 and three pairs of open-reading frames 
with unknown roles in mating are present in the MTL locus of C. albicans as well, which 
are missing in the mating-type (MAT) locus of S. cerevisiae.  Convincing evidence on 
the mating of C. albicans came from two independent reports which observed the mating 
between the manipulated strains in the laboratory (50, 76).  Both research groups 
constructed homozygous a and ɑ strains with different auxotrophic markers using a 
heterozygous a/ɑ parental strain, dominant in natural population, and selected the 
prototrophic mating products.  They obtained the expected prototrophic strain after 
mixing the two auxotrophic homozygous parental strains and the mating products are 
found to be mononuclear and tetraploidy.  Later, the mating process of the C. albicans 
was further studied and described in more details (7, 69) and figure 2 briefly summarizes 
current understandings of the process in C. albicans. 
 
Incorporation of white-opaque switching, a phenotypic switching discovered by Slutsky 
et al (117), in the mating is a major feature of C. albicans that is different from S. 
cerevisiae.  In this phenotypic switching, cells switch from the white-phase form, 
appearing round and forming dome-shaped colonies on plates, to opaque-phase form, 
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appearing elongated and forming flatter and darker colonies on plates.  In addition to the 
difference in the cell morphology, the rate of switching between white and opaque phase 
varied in different direction and transcriptional profiles of cells in different phases are 
different as well.  In the nature environment, C. albicans cells have a predilection for 
white phase as the result of a much higher frequency of switching in the opaque-to-white 
direction (95) and there are about 400 genes in total that are differentially regulated 
between the two phases (62, 126).  Connections between the mating and the phenotypic 
switching were found by Miller and Johnson (79), including the regulation of the 
phenotypic switching by genes present in MTL locus and a much higher efficiency of 
mating in cells of opaque phase versus white-phase cells.  However, the exact role of 
white-opaque switching in the mating of C. albicans is not very clear and one possibility 
is that its incorporation is to restrict the occurrence of mating to certain host niche with 
appropriate environment. 
 
Many components of the mating pathway in C. albicans have been identified, including 
ɑ pheromone, some mating regulators, and proteins involved in the mating signal 
transduction cascade.  The mating pheromone produced only by ɑ cells has been found 
in many laboratories (8, 62, 70) and its precursor is encoded by MFɑ.  In order to obtain 
the mature mating pheromone, the precursor needs to be further processed by Kex2p.  
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As mentioned above, mating regulators are also important components of the mating 
pathway.  Those identified in C. albicans include four transcriptional factors.  Most of 
them have similar functions to their counterpart in S. cerevisiae, while some major 
differences between the two organisms in mating regulators are worth notice (126).  
Compared to S. cerevisiae, C. ablicans has a novel positive transcriptional regulator 
Mtla2p, an activator of a-specific genes, while the function of Mtlɑ2p as a repressor to 
regulate the expression of a-specific genes in S. cerevisiae is absent from the fungal 
pathogen.  In S. cerevisiae MAPK pathway plays a key role in transducing the 
extracellular mating signals into transcriptional responses in the nucleus (32, 65, 107).  
This signaling transduction pathway is conserved in C. albicans.  Many components of 
the signaling pathway in C. albicans are homologous to their counterparts in S. 
cerevisiae and these signaling proteins are required for the mating in C. albicans as well 
(18, 74).  An obvious difference in the signaling cascade between the two organisms is 
the absence of the homologue of S. cerevisiae STE5 in C. albicans, which encodes a 
scaffold protein holding the signaling components together to prevent the interference 
from other signal pathways using the same signaling components.  Furthermore, 
evidence suggests other signal transduction pathways may also be involved in the 
regulation of mating in C. albicans, such as nutritional signals (8, 18, 19, 69). 
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FIG. 2. Steps in the Mating of Candida albicans. Nuclei are depicted in blue and vacuoles in white. 
The parental mating cells are diploid, and the mating products are mononuclear and tetraploid. The 
vacuole is not depicted in the daughter cell (taken from (Bennett and Johnson, 2005))(6). 
                                                                                                                                          25 
 
 
 
2.3 Developments in the Genetic Manipulation of C. albicans 
Genetic manipulation of C. albicans is still a challenging task for researchers after 
decades of extensive exploration.  Many factors contribute to the difficulties in 
manipulating the genome of C. albicans and most of them are related to the unique 
features of this fungal pathogen, including the lack of a defined sexual cycle (86), its 
diploid DNA content (5, 52), lack of plasmids that can be transformed with high 
efficiency, different usage for CUG codon (103), and a few selective markers available.  
 
In the genetic manipulation of C. albicans, the limited number of selective markers can 
be divided into three types.  The first one is the nutritional markers and manipulation 
using this type requires a special parental strain which is engineered to be auxotrophic 
for growth on the media without the supplement of nutrients specified by the selective 
markers.  The first nutritional marker that is widely used in C. albicans is URA3 marker.  
It was Fonzi and Irwin who made the first reliable strain, CAI4, for introduction of 
mutations using this marker (35).  Although the use of URA3 marker offered many 
advantages and many methods were developed based on this marker to manipulate the 
genome of C. albicans, its drawbacks gradually appeared during the extensive 
applications.  A major problem is that the expression of the URA3 at ectopic loci can 
affect the virulence, adherence, and hyphal morphogenesis of C. albicans (11, 20, 64).  
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To overcome the drawback, the use of LEU2, HIS1, ARG4 as nutritional markers has 
been evaluated and corresponding auxotrophic strains were constructed (85).  The 
second type is the drug resistance markers.  Compared to the nutritional markers, using 
this type of markers in genetic manipulations doesn’t need to create auxotrophic strains 
or worry about the influence of the nutritional status on the genes of interest.  To my 
knowledge, IMH3 marker, conferring resistance to mycophenolic acid (MPA), might be 
the first drug resistance markers used in the genetic manipulations of C. albicans (57, 
141).  Another two useful drug resistance markers are SAT1 and CaNAT1, encoding 
streptothricin acetyltransferase and nourseothricin acetyltransferase respectively (92, 
113).  Both these two dominant markers confer the resistance to nourseothricin in C. 
albicans.  Recently, fluorescent markers are used in the disruption of target genes in C. 
albicans, such as green fluorescence protein (GFP) marker, and codon-optimized 
luciferase markers from firefly and Renilla (30, 82, 118).  
 
To manipulate the genes in C. albicans, many strategies and gene cassettes, assisting the 
disruption of genes of interest, have been developed (briefly introduced in figure 3). 
Advantages and drawbacks of some popular methods and cassettes were discussed here.  
These methods and cassettes can be classified into two major classes according to 
whether their target genes are essential or not.  To disrupt a non-essential gene, methods 
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such as URA Blaster method, URA Flipper method, method using UAU1 cassette, and 
their derivatives are widely used.  URA Blaster method makes use of the auxotrophic 
strain CAI4 and URA3 nutritional marker to disrupt the genes of interest.  The nutritional 
marker can be recycled in this method for next round of disruption by looping out the 
marker from the genome.  In addition, the excision of the URA3 marker can be counter-
selected on 5-Fluoroorotic acid (5-FOA).  However, the auxotrophic strain used in this 
method, CAI4, was shown to have defects in expressing certain proteins compared to the 
wild-type strain SC5314 (11) and the method does leave one copy of the hisG sequence 
in the target site which might influence the expression of the adjacent genes. 
Furthermore, the counter selection of the URA3 marker requires a potential mutagenic 
agent, 5-FOA (131).  Compared to the URA Blaster method, URA Flipper method (83) 
avoids the use of the mutagenic agent to counter select for its nutritional marker URA3, 
however the recycling of the marker requires nutritional changes from normal growth 
media to Yeast Carbon Base and Bovine Serum Albumin, pH4.0 (YCB–BSA) medium.  
The URA Flipper method also leaves behind a FRT sequence in the genome but much 
shorter compared to the hisG sequence left by the URA Blaster method.  Both the two 
aforementioned methods need several cloning steps to disrupt a gene of interest in C. 
albicans, but Enloe et al. developed a novel strategy based on the UAU1 cassettes they 
made, which is able to disrupt both two alleles of the gene of interest with just one 
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transformation step (33).  This gene cassette contains a URA3 marker that is disrupted 
by AGR4 marker and when the ARG4 marker is looped out due to the spontaneous 
homologous recombination, the URA3 marker regained its functions.  Thus, 
simultaneous selection of both the two markers could identify the double-deleted 
transformants.  Use of this method doesn’t require both the nutritional change and the 
mutagenic agent, but the URA3 marker will be left in the locus of the disrupted genes, 
which, as mentioned above, may bring some concerns.  
 
Compared to the disruption of a non-essential gene, disruption of an essential gene 
requires a more complicated system and usually more cloning steps to make sure the 
expression of the essential gene only under permissive conditions.  Two popular 
approaches to make the conditional mutants are the gene replacement and conditional 
expression (GRACE) method (96) and a method (89) based on the “Tet-On” system 
constructed by Gossen et al (45).  In the GRACE method, one copy of an essential gene 
is disrupted while the other is engineered to be controlled by the tetracycline (figure 3-
line 10).  The tetracycline (Tet) regulation system used in GRACE method turns off the 
expression of the target gene in the presence of the Tet.  In contrast, both two native 
copies of essential genes are deleted in the method using the “Tet-On” system.  The 
requirement of the essential gene in this approach is satisfied by integration of a cassette 
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FIG. 3. Genetic Manipulation Tools of Candida albicans. The figure shows the various constructs 
used for gene manipulation in C. albicans. The gene of interest and/or flanking sequences are shown 
in green. All sequences coming from different species have been codon optimized to be used in C. 
albicans. Line 1. URA blaster (Fonzi and Irwin,1993), 2. URA flipper cassette. p; promoter region of 
given gene, t; termination sequence of given gene. (Morschhäuser et al., 1999), 3. PCR amplifiable 
URA3 disruption cassette (Wilson et al., 2000), 4. UAU1 cassette (Enloe et al., 2000), 5. PCR 
amplifiable marker cassettes from non-albicans species. C. d.; Candida dubliniensis, C. m.; Candida 
maltosa. (Noble and Johnson, 2005), 6. Cre-loxP system (Dennison et al., 2005), note that when this 
construct integrates, the arg4 sequences will be flanked by loxP sites, 7. “MPAR flipper” cassette 
(Wirsching et al., 2000), 8. SAT1 flipper cassette (Reuss et al., 2004), 9. CaNAT1-FLP cassette. Ag; 
Ashbya gossypii. (Shen et al., 2005), 10. “Tet-Off” system (Roemer et al., 2003), and 11. “Tet-On” 
system (Park and Morschhäuser, 2005) (taken from (Samaranayake and Hanes, 2011)) (99).  
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containing a copy of the gene and MPA resistance marker flanked by FRT sites into the 
ACT1 locus.  The “Tet-On” system constructed in another cassette is introduced into an 
ADH1 locus and will loop out the cassette carrying the target gene by expressing the 
FLP recombinase gene when Tet or its derivative is present. 
 
Many strategies and genetic systems have been developed for C. albicans in the past two 
decades, which benefits the research community of this fungal pathogen.  However, 
compared to other model microbial systems, more genetic tools and selective markers 
are required for C. albicans. 
 
2.4 Evolutionary Studies 
2.4.1 Systems Used to Study the Adaptive Evolution of C. albicans 
Evolutionary studies on the emergence of drug resistance in C. albicans are categorized 
into two major types based on the systems used to evolve the parental strains.  In the first 
type, strains are isolated either from the patients receiving antifungal therapy (111, 134) 
or animal models established to study the pathogenesis of different types of Candidiasis, 
especially the murine models (3, 4).  In vivo systems are used in this type of study, 
which provides ideal tools to study how the drug resistance emerges and expands in the 
whole population in a more realistic situation.  However, variables such as population 
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size inside the host, genetic compositions of the founding pathogen population, and host 
physiological states are difficult to control in vivo.  These factors are likely to alter the 
evolutionary outcomes and make evolution experiments based on these in vivo systems 
difficult to reproduce. 
 
Another type of system used in evolutionary studies is the in vitro system where cell 
populations are evolved in more controllable and reproducible environments. The 
genotypes and population size of the starting population as well as the selection strength 
can all be readily controlled, allowing reproducibility of the environmental conditions 
for each experiment.  In vitro systems can be further divided into two types, either the 
batch serial transfer (24-26) or the continuous cultures (48).  In batch serial transfer 
experiments, the population is grown either on solid or liquid media, and a small fraction 
is serially transferred to fresh media containing the antifungal agent periodically.  The 
population undergoes different growth phases during batch cultivation, as the nutrient 
content of the environment and the physiological state of the cell both change as a 
function of time.  Compared to the batch serial transfer, continuous culture systems 
provide a more constant environment, which helps to keep cells in physiological steady-
state.  In addition, continuous culture systems greatly reduce the bottleneck effect which 
causes a significant loss of rare beneficial mutations and favors the selection of 
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deleterious mutations.  Although in vitro systems may not exactly mimic the realistic 
environments, antifungal resistant mechanisms developed in vivo have not been found to 
be different from those in vitro.  Therefore, in vitro systems can provide important and 
useful information on the drug resistance development during the evolution. 
 
2.4.2 In vivo Evolution of C. albicans in the Presence of Antifungals 
Although evolutionary studies are extremely useful in understanding the drug resistance 
development of C. albicans population, only a few studies are available.  In in vivo 
studies, strains either isolated from animal models treated with antifungal agents or 
patients receiving the antifungal therapy are usually under the investigation to track the 
alteration in drug susceptibility of the isolates or the change in the transcriptional 
profiling during the evolution.  This type of studies not only benefits to the identification 
of pathogenesis-related genes which may serve as novel drug targets but also to the 
rational design of the novel dosing regimens of current drugs. 
 
In one study people investigated the impact of different fluconazole dosing regimens, 
including different dose levels and dosing intervals, on the selection of the isogenic 
resistant strains from six different heterogeneous populations, each consisting of a 
predominant drug-susceptible strain and an isogenic drug-resistant one, during a short-
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term in vivo evolution of C. ablicans using a murine model (3).  For the same total dose 
level, they found the growth of resistant strain was less when it was administrated at a 
lower but more frequent dosage compared to higher but more infrequent one.  The drug 
exposure was further correlated with the outgrowth of the isogenic resistant cell 
population when it was expressed by either the range of T>MIC or 24-h AUC/MIC 
value and these relationships were independent of the type of resistant mechanism 
possessed by the populations.  The results were confirmed by another study from the 
same group which used the same murine model, but cell populations were evolved from 
a single drug-sensitive strain instead of a mixed-inoculum for a month (4).  These studies 
suggest different selection strategies may have different impacts on the expansion of the 
drug-resistant genotypes in the population, develop different population dynamics and 
ultimately lead to different evolutionary outcomes.  In addition, population structure 
prior to the evolution is another important factor.  One piece of evidence came from the 
aforementioned short-term evolution study (3).  They found if populations initially 
contained at least 10% of drug-resistant clone, the evolved populations would behave 
phenotypically as entirely drug-resistant, suggesting that the population structure plays a 
key role in determining the evolutionary outcome.  Thus, no matter what selection 
strategy was adopted, the expansion of the drug-resistant phenotype in the entire 
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population seems cannot be prevented when the population size of the drug-resistant 
mutants grows big enough. 
 
Researchers also studied the change of mRNA level of three candidate genes, including 
CDR1, MDR1, and ERG16, in a series of 17 clinical isolates from a HIV-infected patient 
over two years (134).  They successfully correlated the increase in mRNA level of the 
genes with the increased drug resistance of the isolates based on the timing of the two 
events.  What they found clearly showed multiple mechanisms can occur in the same cell 
line simultaneously and contribute to the final drug-resistance level. 
 
2.4.3 In vitro Evolution of C. albicans in the Presence of Antifungals 
Similar to the in vivo evolutionary studies little information on drug resistance 
development of C. albicans during the in vitro evolution is available.  Among the few 
relevant studies Cowen et al. did a series of elegant work to pave the way for the 
investigations of the in vitro adaptive evolution of this fungus.  They evolved 6 replicate 
populations, found from a single drug-susceptible clone, both in the presence and 
absence of fluconazole over 330 generations using the serial batch transfer method and 
monitored the cell populations’ adaption to the inhibitory concentration of fluconazole 
(26).  By observing the change of fluconazole MIC over time in replicate populations 
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Cowen et al. found population evolution may take different adaptive paths, indicated by 
the significantly different trajectories of the increase in their fluconazole MICs and 
different drug resistance level achieved at the end of the evolution.  The highest 
fluconazole MIC value achieved is 128-fold larger than the lowest one among these 
replicate populations.  These observations suggest that the acquisition of the drug 
resistance in these replicate populations is a random process and thus chance plays a key 
role in the drug resistance development process.   
 
The seemingly random process of drug resistance development raises an interesting 
question: whether or not the fungal populations will converge on similar adaptive paths 
under the selection of an antifungal agent.  Cowen et al. further checked the genome-
wide gene expression patterns of several replicate populations evolved from their 
previous work (26) and found that the evolution of C. albicans in the presence of the 
fluconazole might converge on a limited number of adaptive paths at the transcriptional 
level based on the similarity of genome-wide expression profiles between replicate 
populations (25).  In addition, they analyzed the expression patterns of ten genes, either 
showing the largest changes in microarrays or involving in the drug resistance, in many 
drug-resistant clinical isolates and confirmed the patterns identified in vitro are also 
common to those evolved in vivo. 
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Furthermore, they measured the relative fitness of the evolved populations to a 
genetically marked wild-type strain both in the presence and absence of the drug (24).  
They found fluconazole MIC value and other growth parameters of those drug-exposed 
populations cannot be used to predict their fitness over the wild-type strain in the 
presence of the drug.  Fluconazole MIC value is well-accepted as an indicator to 
evaluate the resistance of C. albicans to the drug.  However, the discordance between the 
MIC value and the fitness results showed MIC itself may not sufficiently predict the 
response of C.albicans to antifungal treatments.  Moreover, the study suggests the 
adaptation to the culture condition or general environment may lead to an improved 
fitness in the presence of drug. 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Yeast Media 
All media were autoclaved at 121°C.  Heat sensitive substances were sterile filtered and 
added to the media (~56°C) afterwards.  For all plates, the final concentration of agar is 
2% (wt/vol). 
 
Rich medium: 
Rich medium (YPAD) was prepared with 1xYPD and adenine added to a final 
concentration of 40μg/ml. 
 1xYPAD 
Yeast extract 10g/l 
Peptone 
Dextrose 
20g/l 
20g/l 
Adenine 40mg/l 
NAT-plates: Nourseothricin (100 mg/ml, H2O) was added to a final concentration of 
400μg/ml. 
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Minimum medium (MM): 
Minimum medium was prepared with YNB without amino acid (AA) and ammonium 
sulfate (AS), 0.5% (wt/vol) ammonium sulfate and either 0.2% (wt/vol) or 2% (wt/vol) 
glucose for different purpose.  
 1xMM (0.2% glucose) 1xMM (2% glucose) 
YNB w/o AA & AS 1.7g/l 1.7g/l 
Ammonium sulfate 5g/l 5g/l 
Dextrose 2g/l 20g/l
 
3.1.2 Buffers and Solutions 
All the buffers and solutions (table 2) used in this study were either autoclaved or sterile 
filtered. 
 
3.1.3 Chemicals and Computing Software 
Chemicals used to make buffers, solutions, and culture media in this study were listed in 
the table 3.  The table 3 also shows the computing software used in this study to perform 
the plasmid analysis and the flow cytometry analysis. 
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TABLE 2. Buffers and Solutions Used in This Work 
Buffer/ solution  Chemical Concentration 
LiAc/TE LiAc 100 mM 
 TE, pH7.5 1 X 
PBS NaCl 137 mM  
 KCl 2.7 mM  
 Na2HPO4 10 mM  
 KH2PO4 2 mM  
PEG/TE/LiAC LiAc 100 mM 
 TE, pH7.5 1 X 
 PEG (3350) 0.4 g/ml 
TBE Tris-borate 45 mM  
 EDTA 1 mM  
TE Tris-Cl 100 mM  
 EDTA 10 mM  
50/50 TE Tris-Cl, pH8.0 50 mM  
 EDTA 50 mM  
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TABLE 3. Chemicals and Computing Software Used in This Study 
Manufacturer Location Chemicals 
ACROS USA D(+)-glucose, Adenine 
Becton Dickinson USA Peptone, agar, Yeast Nitrogen 
Base 
EMD Chemicals Germany Yeast extract, (NH4)2SO4, 
NaCl 
Electron Microscopy Science USA PEG 3350 
Fisher Scientific USA EDTA 
Jena Bioscience Germany Nourseothricin 
LKT laboratories USA Fluconazole 
MP Biomedicals USA LiAc 
Promega  USA Tris-Cl 
VWR USA KaCl, KH2PO4, Na2HPO4 
 
Software Manufacturer Location Resource 
MacVector v11 MacVector, Inc USA CD, license 
CellQuest Pro BD Biosciences USA CD, license 
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3.1.4 Organisms 
TABLE 4. Fungal Strains Used in This Study 
Strain Genotype Reference 
SC5314 C. albicans wild type strain William Fonzi via Magee lab 
KKCa-14 Isogenic to SC5314; ENO1-RFP-NATI This work 
KKCa-17 Isogenic to SC5314; ENO1-GFP-NATI This work 
KKCa-20 Isogenic to SC5314; ENO1-YFP-NATI This work 
 
 
 
3.2 Methods 
3.2.1 Cultivation and Storage of C. albicans 
C. albicans strains were cultured at 30℃ in liquid or solid YNB medium supplemented 
with 0.5% (wt/vol) ammonium sulfate and 2% (wt/vol) D-glucose unless otherwise 
specified.  For selection of nourseothricin resistant transformants, YPAD agar plates 
supplemented with 400μg/ml nourseothricin were used.  For short term storage cells 
were kept on YNB plates at room temperature in the dark.  For long term storage the 
cells were suspended in ~17% sterile glycerol and then stored in cryogenic tubes at -
80℃. 
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3.2.2 Transformation of C. albicans by Heat Shock 
For heat shock transformation, we used a modified lithium acetate method (44).  Cells 
were first grown overnight at 30℃ in YPAD broth to 1-2×108 cells/ml and then diluted 
to 2-5×l06 cells/ml in fresh YPAD medium.  The diluted cells were incubated at 30℃ to 
reach a density of 1×108 cells/ml.  The cells were harvested by centrifugation, washed 
twice with 10 ml sterile water, once with 10 ml LiAc/TE (table 2), resuspended in 
LiAc/TE to give ~2×109 cells/ml, and incubated at 30℃ for 15 min without agitation.  
Cells were then distributed into 50μl aliquots and following solutions were added in 
sequence: DNA fragments to transform, 50 μg heat-denatured salmon sperm DNA, 300 
μl PEG/TE/LiAC (table 2).  After mixing thoroughly the cells were incubated at 30℃ 
for 30 min, heat-shocked at 42℃ for 20 min and pelleted.  The supernatant was 
completely removed and cell pellet was resuspended in 1 ml YPAD broth and plated on 
selective plates after 3 hours of incubation at 30℃.    
 
3.2.3 Construction of Fluorescent C. albicans Strains 
All strains used in this work are isogenic derivatives of the C. albicans strain SC5314 
(table 4).  Three different fluorescent cassettes, each containing a NAT1 marker and a 
fluorescent protein (either red fluorescent protein [RFP], green fluorescent protein [GFP], 
or yellow fluorescent protein [YFP]), were amplified by PCR from plasmids pMG2261, 
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pMG2120, and pMG2263 (table 5), respectively, using two different sets of primers 
(table 6).  The primers for PCR amplifying GFP and YFP cassettes were Ca_Y/GFP_Fp 
and Ca_Y/GFP_Rp.  The primers for amplifying the RFP cassette were Ca_RFP_Fp and 
Ca_RFP_Rp.  The resulting PCR products were then transformed into strain SC5314 to 
form a translational fusion of fluorescent cassettes to the 3’ end of the ENO1 gene in the 
chromosome by homologous recombination.  Transformants were selected on yeast 
extract-peptone-dextrose plus adenine (YPAD) agar plates with nourseothricin 
(400μg/ml), and the fluorescence of each strain was confirmed by microscopy. 
 
 
 
TABLE 5. Plasmids Used in This Study 
Name Marker Description Reference 
pMG2120 Amp/NAT Carries GFP Maryam Gerami-Nejad 
pMG2261 Amp/NAT Carries RFP Maryam Gerami-Nejad 
pMG2263 Amp/NAT Carries YFP Maryam Gerami-Nejad 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                          44 
 
 
 
TABLE 6. Oligonucleotides Used in This Study 
Name Sequence Description 
Ca_Y/GFP_Fp 5’-GAGAATCGAAGAAGAATT 
AGGTTCTGAAGCTATCTACGC 
TGGTAAAGATTTCCAAAAGGC 
TTCTCAATTGGGTGGTGGTTCT 
AAAGGTGAAGAATTATT-3’ 
Forward primer to amplify the 
YFP or GFP cassette from 
pMG2263 and pMG2120 
respectively 
Ca_Y/GFP_Rp 5’-TTTAATTAGTTCATATATTC 
AAGATGTTCCTATAAAAGAAA 
AAAAAAGCACCAGCTTTTTTTT 
ATTTAATCGTAAAACGACGGC 
CAGTGAATTC-3’ 
Reverse primer to amplify the 
YFP or GFP cassette from 
pMG2263 and pMG2120 
respectively 
Ca_RFP_Fp 5’-GAGAATCGAAGAAGAATT 
AGGTTCTGAAGCTATCTACGC 
TGGTAAAGATTTCCAAAAGGC 
TTCTCAATTGGGTGGTGGTGA 
TAACACTGAAGATGTTATT-3’ 
Forward primer to amplify the 
RFP cassette from pMG2261 
Ca_RFP_Rp 5’-TTTAATTAGTTCATATATTC 
AAGATGTTCCTATAAAAGAAA 
AAAAAAGCACCAGCTTTTTTTT 
ATTTAATCGTAAAACGACGGC 
CAGTGAATTC-3’ 
Reverse primer to amplify the 
RFP cassette from pMG2261 
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3.2.4 Adaptive Evolution of C. albicans 
Cells expressing each fluorescent protein (GFP, YFP, or RFP) were mixed together in 
approximately equal numbers (as confirmed by flow cytometry) at the start of parallel 
chemostat (30 ml each) evolution experiments in YNB supplemented with 0.5% (wt/vol) 
ammonium sulfate and 0.2% dextrose (the limiting nutrient) with or without fluconazole.  
The populations evolved at steady state at 30°C at a dilution rate (D) of ~0.2 h-1.  In 
chemostat experiments, the generation time is determined by the dilution rate.  Using a 
dilution rate of 0.2 h-1, the generation time is calculated as ln(2)/0.2, or 3.5 h/generation.  
Two parallel series of evolution experiments were conducted; each series contained one 
control population (no fluconazole) and one population exposed to stepwise increases of 
fluconazole, starting with 0.25μg/ml and increasing the concentration by 4-fold every 50 
to 70 generations.  Samples were taken every 7 to 14 generations, and a portion (1.5 ml) 
of the cells was frozen in 17% glycerol for future analysis.  Cell concentrations were 
measured using a hemocytometer, and the relative proportions of the three 
subpopulations (GFP, YFP, and RFP) were measured using a FACScan flow cytometer 
(BD Biosciences, San Jose, CA). 
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3.2.5 Identification and Isolation of Adaptive Mutants 
At the conclusion of the evolution experiment, we identified the time point samples 
likely to have a substantial fraction of an adaptive clone in one of the fluorescently 
marked subpopulations, based on the dynamics of the relative subpopulation sizes.  
Specifically, we identified the time point sample in which an expanding colored FP 
subpopulation appeared to reach its maximum proportion of the population.  Population 
samples from the generation at which the expanding subpopulation reached a maximum 
proportion were plated on YNB plates.  Using a Dark Reader (Clare Chemical), which 
can distinguish GFP-, YFP-, and RFP-expressing cells, at least seven isolates expressing 
the colored fluorescent protein of the expanding subpopulation were picked for fitness 
measurements.  For all isolates from the same adaptive event, we performed pairwise 
competition experiments by growing each isolate in continuous culture together with the 
previous adaptive mutant (for the first observed adaptive event, the isolates were 
individually competed against the parental strain of a different FP).  The experiments 
were carried out in the presence of the same concentration of fluconazole used during 
the evolution of those isolates.  Of the seven or more clones tested from each observed 
adaptive event, the clone with the highest fitness coefficient was chosen as the adaptive 
clone for that adaptive event, except in cases where multiple isolates exhibited similar 
fitness coefficients.  In those cases, an arbitrary isolate was chosen from the fittest group. 
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3.2.6 Pairwise Competition Experiments 
Chemostat experiments in YNB with 0.2% dextrose and 0.5% (wt/vol) (NH4)2SO4 and in 
the presence or absence of fluconazole were initiated with approximately equal numbers 
of the two clones to be competed (each carrying a different FP marker).  The pairwise 
competition experiments were conducted at 30°C with a dilution rate of ~0.2 h-1.  
Samples were taken every 1 to 5 generations, and the relative proportions of each of the 
two clones were measured using flow cytometry.  The data were plotted on a linear scale 
with ln[x/(1-x)] versus t, where x is the fraction of the sample clone and t is generations.  
The relative fitness coefficient was determined from the slope of the linear region of the 
curve using linear regression analysis.  For statistical analysis, the relative fitness 
coefficients between pairs of the fluorescently labeled parental strains were measured 
either in the absence of fluconazole or in the presence of 0.25 μg/ml of fluconazole.  A 
minimum of three biological replicates were performed for each pairwise competition 
experiment.  A Student t test was used to determine whether the relative fitness 
coefficients measured for the adaptive mutants were statistically significant (P value 
cutoff, 0.05). 
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3.2.7 Fluconazole Susceptibility Assays 
Adpative mutants were first grown in YNB broth overnight at 30℃ overnight and then 
transferred to RPMI 1640 agar plates.  The fluconazole MIC for each adaptive mutant 
was determined in RPMI 1640 plates with an Etest strip according to the manufacturer’s 
instructions (bioMe´rieux SA, France).  3 biological replicates were made for each 
adaptive isolates and the highest MIC value was reported. 
 
3.2.8 Stability Assays for Adaptive Mutants 
One of the parent strains (KKCa-14) and all isolated adaptive mutants from the DP-1 
and DP-2 populations underwent stability tests in the absence of fluconazole.  The 
strains were first plated on YNB plates supplemented with 2% dextrose, and a single 
colony was picked up and transferred into fresh YNB broth.  Five microliters of cell 
culture for each strain was inoculated into 5 ml fresh YNB broth to make a 1,000-fold 
dilution and then was incubated at 30°C for 24 h.  The transfer was repeated for two 
more days (for a total of ~30 generations).  The optical density of the cell culture was 
measured at 600 nm before each transfer.  Fluconazole susceptibility assays were 
performed for each strain to test the stability of the drug resistance after long-term 
incubation in serial batch transfer in the absence of the drug. 
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3.2.9 CHEF Karyotype Analysis 
Preparation of cells for contour-clamped homogeneous electric field (CHEF) karyotype 
analysis was performed as described previously (108).  Whole-chromosome separation 
was performed on a Bio-Rad CHEF-DR III with the following program: 60- to 120-s 
switch, 6 V/cm, 120° angle for 36 h, followed by a 120- to 300-s switch, 4.5 V/cm, 120° 
angle for 12 h.  SfiI digestion of CHEF gel plugs was performed using the following 
procedure.  A portion of whole-chromosome CHEF plugs were washed twice for 10 min 
each time in 1 ml of 10 mM Tris (pH 8.0), 1 mM EDTA (TE buffer) and then incubated 
in 1 ml of TE buffer containing 0.1 mM phenylmethylsulfonyl fluoride for 10 min.  The 
plugs were washed twice as before and incubated in 500 μl of SfiI restriction enzyme 
buffer containing bovine serum albumin (BSA) at 100 μg/ml for 15 min, and 40 units of 
SfiI enzyme was added.  The SfiI-treated plugs were then incubated overnight at 50°C, 
washed in 100 mM EDTA (pH 8.0), added to a 1% Megabase agarose gel (Bio-Rad, 
Hercules, CA) in 0.5 × TBE buffer (table 2), and separated as previously described (112). 
 
3.2.10 Ploidy Analysis 
Strain ploidy was examined by flow cytometry.  C. albicans strains were grown to log 
phase, and ~4 ×106 cells were collected in a round-bottom microtiter plate by 
centrifugation.  The pellets were resuspended in 20 μl of 50/50 TE (table 2); 180 μl of 
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95% ethanol was added dropwise, and the suspensions were stored overnight at -20°C.  
The ethanol-fixed cell pellets were washed twice with 200 l of 50/50 TE, resuspended in 
200 μl of RNase A at 500 μg/ml in 50/50 TE, and incubated for 2 h at 37°C.  The cells 
were centrifuged again, and the pellets were incubated in 200 μl of 1 mg/ml proteinase K 
in 50/50 TE for 2 h at 37°C.  The cells were centrifuged again and washed in 50/50 TE, 
and the pellets were resuspended in 50 μl of Sybr green I (1:85 dilution; Invitrogen, 
Carlsbad, CA) in 50/50 TE and incubated overnight in the dark.  Finally, the cells were 
centrifuged, the pellets were resuspended in 700 μl 50/50 TE, and ploidy was detected 
and analyzed on a FACScaliber flow cytometer (BD Biosciences, San Jose, CA).
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4. IN VITRO EVOLUTION OF C. albicans DURING THE EXPOSURE TO A 
STEPWISE INCREASE IN FLUCONAZOLE CONCENTRATION 
 
4.1 Introduction 
The emergence of antifungal drug resistance in microbial pathogens is a process of 
adaptive evolution.  Depending on many factors, such as population size, rate of 
mutation, and fitness effects, pathogen populations may be heterogeneous during the 
evolution in the presence of the antifungal agents, consisting of multiple beneficial 
mutations which compete for expansion in a process called “clonal interference” (28, 42).  
Determining the evolutionary dynamics during the adaption to the drugs is important for 
understanding the fundamental process and mechanisms underlying the emergence and 
spread of drug resistance at the population level. 
 
Little information is available on the evolution of C. albicans in the presence of the drug, 
such as the frequencies with which adaptive mutants arise and expand, the evolutionary 
trajectories (the order of occurrence of adaptive mutations), and the potential 
convergence or divergence in the adaptive mechanisms between parallel populations.  
These are important to better understand how the pathogen evolves drug resistance in the 
hosts undergoing antifungal treatments.  In addition, they will be useful in predicting the 
trajectory of a clinical infection and in rational design of appropriate therapeutic 
strategies. 
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C. albicans is an opportunistic fungal pathogen of clinical importance, causing mild 
superficial mucosal infections as well as life-threatening systemic infections. Rapid 
emergence of drug resistance was observed in the fungus both in in vitro and in vivo 
studies.  Drug-resistant mechanisms have been extensively studied for this organism.  In 
C. albicans, drug resistance can be acquired through many ways, including point 
mutations, loss of heterozygosity, and gross chromosomal rearrangements (109, 111, 
112). However, more novel mechanisms are still required to be uncovered, as suggested 
by a study of a collection of drug-resistant clinical isolates (136).  About 50% of the 
collected isolates in that study have unknown mechanisms.   
 
Here, we monitored the in vitro evolution of C.albicans during its adaptation to a 
stepwise increase in fluconazole concentration, using the VERT approach which is 
originally designed for S. cerevisiae (53).  Using the VERT system, the evolutionary 
dynamics of C. albicans during the in vitro adaptation to fluconazole was determined, 
which facilitated the identification and isolation of adaptive mutants.  Increased drug 
resistance in the mutants was confirmed by fluconazole MIC measurements.  Fitness 
effects of mutations for each adaptive isolate were evaluated both in the presence and 
absence of the drug by pairwise competition assays.  Since aneuploidy has been 
associated with the drug resistance recently (109, 111), flow cytometry was used to 
analyze the ploidy of the adaptive mutants.  In addition, the major chromosomal 
rearrangements have been checked by CHEF karyotype analysis for adaptive isolates 
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and the DNA contents present at the rearranged parts were determined by a microarray 
analysis.    
 
4.2 Evolutionary Dynamics in the Presence and Absence of Fluconazole 
The VERT system was modified for C. albicans to follow the evolutionary dynamics of 
two sets of parallel populations evolved either in the absence (control populations, CP-1 
and CP-2) or the presence (experimental populations, DP-1 and DP-2) of fluconazole.  
At the start of the adaptive evolution experiments, isogenic strains differing only in the 
expression of different fluorescent proteins (FP) were mixed together in approximately 
equal numbers.  Thus populations were divided into three subpopulations featuring 
different fluorescence and the relative proportions of each subpopulation were recorded 
in real time using the flow cytometry.  For the drug-exposed populations, the initial drug 
concentration was set as 0.25μg/ml which is twice as much as the MIC of the parental 
strains.  The concentration of fluconazole first increased to 1μg/ml at generation 64，
which was followed by a further increase to 4μg/ml at generation 112.  The time point at 
which the drug concentration changed was chosen arbitrarily.  The scheme of our 
chemostat-based continuous culture system used to evolve the parallel populations was 
shown in figure 4 and the evolutionary dynamics for all four parallel populations 
evolved over ~170 generations were shown in figure 5. 
 
 Adaptive events occurred in subpopulations were identified by observing the expansions 
of those subpopulations in their relative proportions and clones that were likely to be 
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responsible for the observed adaptive events were isolated and named systematically 
according to the population from which they were isolated and the sequence in which 
their corresponding expansions were observed.  For example, DP-1-M1 clone was the 
adaptive mutant isolated from the first observed expansion (M1) from the DP-1 
population. 
 
 
 
 
FIG. 4. Scheme of Chemostat-Based Continuous Culture System. 
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FIG. 5. Evolutionary Dynamics of Replicated Candida albicans Populations. Populations evolved 
either in the absence (CP-1 population [A] and CP-2 population [B]) or presence (DP-1 population [C] 
and DP-2 population [D]) of fluconazole. The colored bars represent the relative fractions of each 
colored subpopulation, RFP (red), GFP (green), and YFP (yellow), as determined using fluorescence-
activated cell sorting (FACS). FLU, concentration of fluconazole in the feed. The subpopulations 
from which the adaptive mutants were isolated are numbered (taken from (Huang et al., 2011 ))(48). 
 
 
 
We assumed that the most competitive clone must exist in a subpopulation that is 
expanding.  According to this assumption, subpopulations expanding just before the 
increase in the concentration of fluconazole will continue to expand in its relative 
proportion after the increase.  Based on the evolutionary dynamics in the presence of 
drug, DP-1 population indeed follows the expected trend.  The subpopulation labeled by 
YFP of DP-1 population started expanding at approximately generation 58 and 
continued its expansion following the first increase in the drug concentration at 
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generation 64.  So does the RFP subpopulation upon the first increase in the drug 
concentration.  The adaptive clone (DP-1-M2) isolated after the first increase in drug 
concentration from the YFP subpopulation indeed showed an increased fitness compared 
to its wild-type strain (KKCa-20) and the previous adaptive clone (DP-1-M1) in the 
presence of the drug (figures 6 and 7, tables 7 and 8), although no increase in the 
fluconazole MIC value was observed when compared to DP-1-M1 strain (0.3μg/ml).  
Furthermore, upon the second increase in drug concentration from 1μg/ml to 4μg/ml, at 
generation 112, the YFP subpopulation which started expanding at approximately 
generation 93 followed the expected continuous expansion as well.  However, the 
isolated adaptive clone (DP-1-M4) from the continuously expanding subpopulation was 
not more competitive than the previous adaptive clone (DP-1-M3) in the presence of 
drug.  Interestingly, the same trend was not observed in another parallel drug-exposed 
population (DP-2 population).  After each of the stepwise increases in the fluconazole 
concentration, a different FP subpopulation started to expand. 
 
Furthermore, evolutionary dynamics were compared between the C. albicans 
populations evolved in the presence and absence of fluconazole.  We found an adaptive 
event occurred every 20 to 50 generations in the controls but more frequently, about one 
event per 10 to 40 generations, in the fluconazole-exposed populations.  The number of 
adaptive events observed over ~170 generations was significantly higher in the drug-
exposed populations than in those not exposed to the drug, with approximately 7 and 10 
adaptive events observed in the two fluconazole-exposed populations while 3 and 4  
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FIG. 6. Relative Fitness Coefficients of Adaptive Mutants against Previous Adaptive Mutants. The 
relative fitness coefficients of DP-1 (A) and DP-2 (B), in the presence of fluconazole (open bars), 
were measured at the drug concentration indicated by the solid line, or without fluconazole (solid 
bars). The data shown are the averages and standard deviations (SD) of a minimum of 3 biological 
replicates. The asterisks indicate that the relative fitness difference measured in the adaptive strains is 
statistically significant (P  0.05, using an unpaired Student t test with unequal variance). The dashed 
line indicates the measured MIC of each adaptive mutant (take from (Huang et al., 2011)) (48). 
 
 
 
adaptive events observed in the control populations. Thus, the addition of the drug 
greatly increased the frequency of the adaptive events in the C. albicans. 
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FIG. 7. Relative Fitness Coefficients of Adaptive Mutants against Parental Strains. The relative 
fitness coefficients of DP-1 (A) and DP-2 (B) were measured both in the presence of 0.25 μg/ml of 
fluconazole (open bars) or without fluconazole (solid bars). The data shown are the averages and SD 
of a minimum of 3 biological replicates. The asterisks indicate that the relative fitness difference 
measured in the adaptive strains is statistically significant (P  0.05, using an unpaired Student t test 
with unequal variance) (taken from (Huang et al., 2011)) (48) . 
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TABLE 7. Adaptive Mutants Isolated from Fluconazole-Exposed and Control Populations 
 
a Fluorescent marker. 
b Fluconazole concentration in the feed. 
c Generation from which the strain was isolated. 
d Relative to previous adaptive mutant. 
NA, not applicable. 
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TABLE 8. Relative Fitness Coefficients of Adaptive Mutants Compared to the Parental Strains 
 
a:  Relative to the parental strain of a different color. 
FLU:  fluconazole.   
Relative fitness in units of per generation. 
 
 
 
4.3 Fluconazole Susceptibility and Stability of the Increased Drug Resistance 
Depending on the susceptibility to antifungal drugs, C. albicans may fail to respond to 
the corresponding antifungal treatments, leading to the clinical failures in treating 
infections caused by the pathogen.  Fluconazole is the most commonly used azole drugs 
in treating Candidiasis due to its low toxicity to patients and good bioavailability.  To 
determine the susceptibility of C. albicans to fluconazole, the isolated adaptive clones 
were plated on RPMI 1640 solid media and fluconazole MIC for each clone was 
determined by an Etest strip at 30℃.  Three biological replicates were made for each 
clone and the highest MIC value was reported (figures 6 and 7, table 7).  Interestingly, 
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the alteration of the MIC in the most competitive clones of the two parallel drug-exposed 
populations followed two different trajectories during the adaptive evolution.  In DP-1 
population, the trajectory of change in the MIC value is increased in a stepwise manner, 
which coincides with the change in the drug concentration to which the population was 
exposed.  However, the MICs in adaptive clones of DP-2 population fluctuated during 
almost the entire evolution process and finally went up rapidly.  Based on the MIC data, 
the majority of the adaptive clones isolated in this work showed higher fluconazole MIC 
values than their parental strains, suggesting their reduced susceptibility to the drug.          
 
The reduced drug susceptibility observed in the adaptive clones could arise from the 
transient physiological response to the environmental stress or from a more stable source, 
genetic mutation.  To figure out which mechanism is likely to contribute to the increased 
drug resistance in our adaptive clones, we performed stability tests, as described in 
Material and Methods, for all adaptive clones isolated from DP-1 and DP-2 populations.  
In stability tests, each clone underwent a series of transfers for about 30 generations in 
the absence of fluconazole and populations after the growth without the drug were 
subjected to fluconazole MIC measurement.  The MICs of the transferred isolates and 
those of the original clones before the serial transfer were compared in figure 8.  
Importantly, the MIC values of all of the adaptive mutants did not decrease following the 
nonselective serial transfer and sometimes even higher than the MIC values of the 
parental strain, suggesting that the drug resistance is stable for a period of at least 30 
generations and is likely due to the more stable genetic change. 
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4.4 Relative Fitness Coefficients in the Presence and Absence of Drug 
Fitness effect associated with a mutation may determine the fate of the mutation in the 
population during the evolution.  Those mutations with fitness advantage are more likely 
to spread and finally dominate the whole population.  Thus, fitness analysis is important 
for understanding the fundamental principles underlying the evolutionary dynamics.  
Fitness coefficients of adaptive clones responsible for observed adaptive events during 
the in vitro evolution were determined relative to two different references either by 
competing the adaptive isolates against the previous adaptive clone (for all isolated 
adaptive clones) or a parental strain with a different fluorescent marker (for isolates from 
drug-exposed population DP-1 and DP-2).  The measurements of the relative fitness 
coefficients were conducted under two different conditions, both in the absence (for all 
adaptive clones) and presence of the drug with the same concentration as when the 
adaptive clones were isolated (for isolates from drug-exposed population DP-1 and DP-
2).  These fitness data were shown in tables 7 and 8 and figures 6 and 7. 
 
Consistent with the reduced drug susceptibility observed in adaptive clones from drug-
exposed populations by MIC measurements, adaptive isolates exhibited significant 
increases in fitness compared to the parental strains in the presence of the drug (figure 7 
and table 8).  However, when compared to the previous adaptive isolates, not all 
adaptive clones gained a fitness advantage in the presence of the drug (figure 6 and table 
7), which is unexpected.  We assumed that the most competitive clone must exist in an 
expanding subpopulation, thus an increase in the fitness compared to the previous 
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adaptive isolates in the presence of drug is supposed to be found for all adaptive clones 
isolated from the expanding subpopulations.  This suggested that a complex interaction 
might exist between multiple genotypes in the evolving populations and contribute to the 
observed evolutionary dynamics. 
 
 
 
 
FIG. 8. Stability of Drug Resistance. Shown are the MIC values for one of the parental strains and all 
of the isolated adaptive mutants from the fluconazole-exposed populations before and after serial 
passage in the absence of the drug for more than 30 generations (Taken from (Huang et al., 2011)) 
(48). 
 
 
 
More importantly, for most of the adaptive clones isolated from the drug-exposed 
populations, the significant increases in the fitness compared to the parental strains in the 
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presence of drug didn’t accompany with a significant fitness cost when the drug is 
removed.  This is especially evident in adaptive clones isolated from DP-2 population 
and most of them exhibited fitness advantage over the parental strains both in the 
absence and presence of the fluconazole (figure 7 and table 8).  In consistent with this 
observation, most of the adaptive clones with reduced drug susceptibility, as indicated 
by the increase in MIC value, didn’t show significant decreases in the fitness compared 
to the parental strains in the absence of drug and instead many exhibited moderate 
increases in the fitness (figure 6 and table 7).  
 
4.5 Ploidy Analysis and Chromosomal Rearrangements 
Using the VERT system we successfully identified and isolated many adaptive clones 
and based on the stability tests stable genetic changes are most likely to be responsible 
for the reduced drug susceptibility and the increased fitness in the presence of the drug 
that observed in these adaptive isolates.  The specific genetic mechanisms conferring the 
drug resistance as well as the fitness advantage to these isolates are of great interest, but 
in this work we just focused on the genetic changes in the chromosome level, including 
the aneuploidy and chromosomal rearrangements. 
 
We first asked if there is any obvious sign of alterations in the ploidy of the adaptive 
mutants by checking the DNA content of their genomes using flow cytometry (table 7), 
since aneuploidy has been shown to be responsible for the drug resistance in many C. 
albicans isolates (109, 111).  The majority of the adaptive isolates from the drug-
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exposed populations seemed to be diploids (2N).  One exception, DP-1-M6, did exist 
and this adaptive isolate exhibited an about 4N genome content, suggesting that it may 
be a tetraploid.  We also performed the ploidy analysis for adaptive clones isolated from 
the populations evolved in the absence of the drug and similar results were obtained.  All 
adaptive clones from these control populations except one, CP-2-M2, had an about 2N 
genome content, suggesting that they are also diploids.  The CP-2-M2 isolate appeared 
to be either a triploid, since it had an about 3N genome content.  Therefore, aneuploidy, 
an important and common resistance mechanism found elsewhere, apparently is not the 
major cause for the improved fitness and drug resistance of the adaptive mutants isolated 
in this study. 
 
We next examined the genome of the adaptive clones from both the drug-exposed 
populations and the control populations by CHEF gel analysis to see if they had obvious 
signs of major chromosome rearrangements (figure 9).  The chromosome 6 and 7 
migrated differently in some adaptive mutants compared to the parental strains, which is 
likely due to the alterations in the lengths of the major repeat sequence tracts (66).  No 
alterations in other larger bands were detected and no ectopic bands were observed.  We 
further treated the genomic DNA of the adaptive clones with SfiI, a restriction enzyme 
which digests the genome of C. albicans into 2 to 3 resolvable bands per chromosome, 
and analyzed the migration pattern of the SfiI-treated genomic DNA.  What we detected 
is the emergence of new bands in two adaptive clones, DP-1-M6 and DP-1-M7, isolated 
from independent lineages (figure 10).  To determine the identity of the DNA present in 
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the new bands, they were excised from the gel and subject to the hybridization to 
microarrays of C. albicans open reading frame (ORFs) (31, 112).  Analysis of the 
hybridization results showed that the new bands from the both cases correspond to a 
region of the chromosome R, spanning the approximate coordinates 1353 to 1907kb.  
The region starts at a major repeat sequence (MRS) and end at a SfiI site just past the 
rDNA repeats.  Therefore, alterations in the lengths of the rDNA repeats are most likely 
to cause the formation of the new bands.  In addition, we didn’t detect the appearance of 
chromosome 5L isochromosome [i(5L)] which is associated with the increased drug 
resistance.  In summary, we didn’t detect any major gross genome rearrangements 
spanning the non-repetitive regions of the genome (110).  According to the ploidy and 
chromosomal-rearrangement analysis, the improved drug resistance of the isolated 
adaptive clones is most likely to be explained either by the single-nucleotide 
polymorphisms (SNP) or other stable genome arrangements that not detected by the 
CHEF analysis. 
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FIG. 9. Karyotype Analysis Using CHEF Gel Separation of Whole Chromosomes. Separation of 
whole chromosomes by CHEF gel electrophoresis and detection of chromosomal DNA by ethidium 
bromide staining. Identity of different chromosomes is indicated on the right. Size differences 
between chromosomes R and 1 are not resolved using the electrophoresis conditions used here (taken 
from (Huang et al., 2011)) (48). 
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FIG. 10. Karyotype Analysis Using CHEF Gel Separation of SfiI-Digested Chromosomes. The arrow 
indicates a novel band migrating in strains DP-1-M6 and DP-1-M7. Subsequent analysis indicated 
that this band corresponds to ChrR and is hypothesized to include altered numbers of rDNA repeats 
(taken from (Huang et al., 2011)) (48). 
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5. DISCUSSION 
 
5.1 Relationship between the Evolutionary Dynamics and Relative Fitness Coefficients 
Theoretically, each adaptive mutant responsible for an adaptive event observed in the 
evolutionary dynamics should outcompete the adaptive mutant isolated from the 
previous adaptive expansion in the pairwise competition experiments when the drug is 
present (e.g., M3 should outcompete M2 from the same population ).  In consistent with 
this, most of the adaptive isolates have a higher fitness coefficient relative to the 
previous adaptive isolates in the presence of fluconazole.  However, some exceptions 
existed in the both two drug-exposed populations.  When competed with the previous 
adaptive mutants in the presence of the drug, DP-1-M6 (generation 146), DP-2-M4 
(generation 64), and DP-2-M7 (generation 112) exhibited a lower reproduction rate, 
suggesting they are more drug-susceptible than the previous mutants.  MIC 
measurements of these adaptive mutants further confirmed this for DP-2-M4 and DP-2-
M7 but not for DP-1-M6.  When the evolutionary dynamics is checked carefully for DP-
1-M5 (generation 134) and DP-1-M6, DP-1-M5 and DP-1-M6 are actually responsible 
for adaptive events which almost occurred at the same time (generation 125), leading the 
expansion of the two subpopulations against the yellow subpopulation simultaneously.  
Thus, DP-1-M6 is not necessarily more drug resistant than the DP-1-M5.  However, DP-
2-M4 and DP-2-M7 are indeed two exceptions.  To account for the apparent discordance 
between the observations from evolutionary dynamics and pairwise competition results 
for the two adaptive mutants, we offered several possible explanations here.  The 
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expansion leading to the isolation of DP-2-M4 was obviously an adaptive event based on 
the evolutionary dynamics, since there are three time points exhibiting the continuous 
increase in the green subpopulation.  Based on the significant expansion rate, the 
proportion of the adaptive mutants DP-2-M4 in the green subpopulation is unlikely to be 
small.  Nonetheless, among the eight colonies randomly isolated from that subpopulation 
at generation 134, no one exhibited increased fitness compared to the previous adaptive 
mutant DP-2-M3.  Thus, either the actual mutant responsible for the adaptive expansion 
was not present in the isolates or the pairwise competition is not able to reproduce a 
potential beneficial interaction between DP-2-M4 and other genotypes in the evolution 
when DP-2-M4 was isolated.  Actually, this type of beneficial interaction has been 
observed in vitro in a long-term adaptive-evolution experiment with Escherichia coli 
under glucose limitation (97), where adaptive mutants that exhibit cross-feeding of 
different metabolites establish a stable coexistence.  Thus, we cannot rule out the 
possibility that complex interactions also contributed to some of the observed expansions 
in the populations that evolved here.  In contrast, the expansion leading to the isolation 
of DP-2-M7 may not be an actual adaptive event and instead it is likely due to the noise 
in the measurements, since the relative proportions of the three FP subpopulations seem 
to be in a quasi-steady state from generation 99 to generation 112 and only one time 
point exhibited the increase in the relative proportion of the corresponding subpopulation 
(green) at generation 112.  Alternatively, the failure of isolation of the actual adaptive 
mutant based on the small expansion rate and the complex interaction between multiple 
genotypes that not existed in pairwise competition may be the possible explanations. 
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5.2 Relationship between the Drug Susceptibility and Relative Fitness Coefficients 
MIC Measurement has been extensively used in evaluating the drug susceptibility of 
fungal pathogens and the correlation of the MIC value with the in vivo drug resistance is 
well reviewed by White et al.(137).  Although the fluconazole MIC value is currently 
used as a key indicator to determine whether C. albicans is resistant to the drug in 
clinical practice, evidence showed that the relationship between the MIC and the ability 
to adapt to an environment with drug present seems not be linear both in vivo and in 
vitro (24, 93).  Thus, we argued that MIC alone may not predict the in vivo cellular 
response to the drug and checked our data to see if it supports this idea.  The ability of 
the C. albicans isolates to adapt to the environment in our short-term evolution 
experiments was expressed in fitness coefficients relative to the previous isolates in the 
presence of the drug, determined in pairwise competition assay.  The MIC values of the 
adaptive isolates were determined by the Etest strip assays (see materials and methods).   
The fitness data of the adaptive isolates was then compared to their corresponding MIC 
values and we found there is no correlation between the relative fitness coefficients and 
MIC values of the adaptive isolates.  For instance, DP-1-M6 showed a significant 
decrease in fitness in the presence of drug relative to DP-1-M5, yet it gained an increase 
in the MIC value relative to DP-1-M5 (table 7).  Similarly, the discordance between the 
MIC and the fitness can also be observed in another strain, DP-2-M9. The increase in the 
fitness of DP-2-M9 relative to the DP-2-M8 in the presence of the drug was 
accompanied with a reduction in the MIC value relative to DP-2-M8.  The inconsistency 
between the MIC and fitness may be mostly likely due to the different growth conditions 
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and methods of measurement: the MIC was determined using Etest strip assays, where 
cells were grown on RPMI 1640 agar plates; The fitness was determined by pairwise 
competition experiments in chemostats with YNB broth containing fluconazole.  
Therefore, our data supports the idea that the MIC alone does not reflect the fitness of a 
strain in the presence of the drug and thus is insufficient to predict the evolutionary 
outcome. 
 
5.3 Fitness Cost of Antibiotic Resistance 
Fitness effect associated with a resistant mutation plays a key role in determining the 
fate of the resistant genotype in the population: it will have a great impact on whether 
the resistant genotype can be maintained and whether the corresponding mutants will 
become dominant in the population.  The fitness effect of a mutation is usually specific 
to the environment where the mutant is exposed and the effect could change among 
different environmental conditions.  This environmental specificity of the fitness effect 
may be described by following four scenarios.  The first scenario is antagonistic 
pleiotrophy (AP), which describes mutations that are beneficial in one condition but are 
deleterious in others.  The second is mutation accumulation (MA), in which mutations 
that are accumulated in one environment occurred by drift are neutral in a given 
environment but are deleterious in another environment.  The third scenario is the 
independent adaptation (IA), which describes mutations with beneficial roles in one 
environment but neutral in others.  And the last scenario is cross adaptation (CA), in 
which mutations is beneficial in both environments. Many microbial drug-resistant 
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mutations have been found to fall in the first scenario, AP, with increased fitness in the 
presence of drug but less competitive when the drug is removed.  Therefore, the 
proportion of the cells carrying this type mutation will decrease or the corresponding 
genotype may even get eliminated from the population in the absence of the drug.  
However, not every resistant genotype with a fitness cost will end in elimination during 
the evolution.  Some studies showed that further evolution in the absence of the drug 
may generate compensatory mutations in these mutants, leading to improved fitness of 
these resistant genotypes (2, 67, 77, 106). 
 
In the short-term adaptive evolution experiments reported here, we observed all 
scenarios described above but MA in the drug-resistant C. albicans isolates.  An 
adaptive clone isolated from one population (DP-1-M5) showed a significant increase in 
the relative fitness compared to the parental strain in the presence of drug.  The fitness of 
the drug resistant isolate decreased compared to the parental strain when the drug was 
removed (see Figure 7), demonstrating a clear case of AP.  However, the majority of the 
isolates fall in the third or fourth categories described above, where mutations that are 
beneficial in the presence of the drug are either neutral or beneficial in the absence of the 
drug (see Figure 7).  Thus, most of the adaptive clones isolated gained increased drug 
resistance while not became less competitive when drug is removed, which is similar to 
other studies of C.albicans (1, 24).  Actually, there are some drug-resistant isolates from 
DP-2 population exhibiting increased fitness compared to the parental strains in the 
absence of the drug (see figure 7).  These resistant mutations are of great interest, since 
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they are more likely to survive the drift and become the dominant genotype in the 
population. 
 
Compared to the adaptive clones isolated from our work, Cowen et al. (24) observed a 
different picture in their study.  Most isolates with increased fitness in the presence of 
the drug compared to the parental strain showed neutral or negative relative fitness in the 
absence of the drug. Interestingly, they observed the MA scenario which is absent in our 
study.  Possible explanations to the difference between our observations and their results 
may be due to the differences in C. albicans strains used for the evolution experiments, 
the media used for the evolution (yeast nitrogen base versus RPMI 1640), and the 
evolution system (chemostat versus serial batch transfer).  The use of serial batch 
transfer method causes a serious bottleneck effect during each transfer.  Thus, it is likely 
that the majority of the beneficial mutations arose may get lost during the course of the 
serial transfers.  In a continuous system, on the other hand, beneficial mutants have a 
higher probability of being retained in the system for further evolution. 
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6. CONCLUSIONS 
 
Evolutionary dynamics of the C. albicans during the drug resistance development is 
critical for understanding the underlying fundamental principles governing the 
acquisition and spreading of the drug resistance within this organism in the population 
level.  While time course samples collected from patients receiving antifungal treatments 
would be the ideal system to study the dynamic drug resistance development process, the 
limited clinical isolates and the complex host-pathogen interaction make the in vivo 
evolutionary dynamics difficult to get and reproduce.  Traditional in vitro studies lack an 
efficient tool to track the appearance and expansion of the adaptive mutants in the 
population in real time and thus little information on the evolutionary dynamics of 
C.albicans is available.  In this work, we addressed the challenges by using the VERT 
system to study the in vitro evolution of the fungus in the presence of stepwise 
increasing fluconazole concentration.  We obtained the evolutionary dynamics for C. 
albicans evolved either in the presence or absence of the drug.  In addition, we 
successfully identified and isolated a series of adaptive clones in a systematic manner.  
The Drug-resistant phenotypes are stable in these isolates for at least 30 generations in 
the absence of the fluconazole and most of the drug-resistant isolates didn’t exhibit a 
fitness cost when the drug is removed.  The known aneuploidy and major genome 
rearrangements associated with drug resistance were not detected in these adaptive 
clones, suggesting SNPs or other stable unknown chromosomal rearrangements may 
contribute to the increased drug resistance.  Furthermore, we detected an increase in the 
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frequency of the adaptive events when the drug is present. The knowledge gained from 
the study may contribute to better understandings of the adaptation to the fluconazole in 
C. albicans.  
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